Skip to content

Tenecteplase

  • Biologic
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Tenecteplase does in the body

Acute ischemic stroke

From the FDA-approved label: Tenecteplase is a modified form of human tissue plasminogen activator (tPA) that binds to fibrin and converts plasminogen to plasmin. In the presence of fibrin, in vitro studies demonstrate that tenecteplase-mediated conversion of plasminogen to plasmin is increased relative to its conversion in the absence of fibrin. This fibrin specificity decreases systemic activation of plasminogen and the resulting degradation of circulating fibrinogen as compared to a molecule lacking this property. , bleeding) or efficacy has not been established.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.

What the registries record it as

  • The substance registry classes this as protein.

    FDA substance registry · WGD229O42W · read 2026-08-29

Where each sentence above came from

No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.

Shown as the opening line on this page.

No statement of the main limit is recorded.

The four opening statements run to 97 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Biomarker

A biomarker is a number from a test that stands in for something about health.

A picture of it, and where the picture fails

A biomarker is like a fuel gauge.

Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.

What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.

A measurable indicator used as a substitute for a clinical outcome of interest.

Placebo

A placebo is a dummy treatment given so the real one can be compared with it.

A picture of it, and where the picture fails

A placebo is like a blank control in an experiment.

Where that stops being true. A blank does nothing. People given a placebo often do get better.

What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.

An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.

Comparator

A comparator is whatever the treatment was measured against.

A picture of it, and where the picture fails

It is like the other runner in a race.

Where that stops being true. A race has one winner. A study can show both arms improved.

What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.

The control condition against which the experimental intervention is assessed.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

modified Rankin scale (mRS) scores

The study did not show it

Who was studied
NCT06352632
How many people
20000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Not recorded

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot

Composite endpoint: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia or in-hospital intracranial hemorrhage (ICH) or in-hospital major bleedings (other than ICH)

The study did not show it

Who was studied
NCT02181985
How many people
5989
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Not recorded

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot

A reduction of functional dependence analyzed across the whole distribution of outcomes assessed on the modified Rankin Scale (mRS),

The study did not show it

Who was studied
NCT06320431
How many people
4000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
What a body can do day to day
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Not recorded

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot

Incidence of major adverse events (MAEs) at 1 year

The study did not show it

Who was studied
NCT07160491
How many people
3356
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Not recorded

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The study did not show it

Who was studied
NCT00623623
How many people
1899
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Not recorded

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot

modified Rankin Scale

The study did not show it

Who was studied
NCT02814409
How many people
1858
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Not recorded

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • FDA label (openFDA SPL) · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • TNKase is a tissue plasminogen activator (tPA) indicated: for the treatment of acute ischemic stroke (AIS) in adults. ( 1.1 ) to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI) in adults. ( 1.2 ) 1.1 Acute Ischemic Stroke TNKase is indicated for the treatment of acute ischemic stroke (AIS) in adults.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “The safety and effectiveness of TNKase in pediatric patients have not been established.”

    US prescribing information · e647640d-c395-4b4b-a0be-1162f9c21d84 · read 2026-08-30

  • On older people, the label states: “Of the total number of TNKase-treated patients within 0-3 hours in Trial 1 for acute ischemic stroke (AIS), 426 (72%) were 65 years of age and older, and 290 (49%) were 75 years of age and older [see Clinical Studies (14.1) ].”

    US prescribing information · e647640d-c395-4b4b-a0be-1162f9c21d84 · read 2026-08-30

  • On people who are pregnant, the label states: “Risk Summary There are risks to the mother and fetus from acute ST elevation myocardial infarction and acute ischemic stroke, which are medical emergencies in pregnancy and can be fatal if left untreated (see Clinical Considerations ).”

    US prescribing information · e647640d-c395-4b4b-a0be-1162f9c21d84 · read 2026-08-30

  • On people who are breastfeeding, the label states: “Risk Summary There are no data on the presence of tenecteplase in either human or animal milk, the effects on the breastfed infant, or the effect on milk production.”

    US prescribing information · e647640d-c395-4b4b-a0be-1162f9c21d84 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Not recorded

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

RNAWiki has not recorded a supervision or regulatory status for this substance.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

No register row and no identity class settled the question.

No source is stored against this line.

What is in the pack

Sold as vial.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Not recorded

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 3 products list this as an active ingredient in the United States drug directory. 3 of them contain it and nothing else.

    FDA National Drug Code directory · 12714-234 · read 2026-08-29

  • They are sold as powder, for solution and solution.

    FDA National Drug Code directory · 12714-234 · read 2026-08-29

  • 2 published labels name it as an active ingredient. 2 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · e647640d-c395-4b4b-a0be-1162f9c21d84 · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · e647640d-c395-4b4b-a0be-1162f9c21d84 · read 2026-08-29

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.

Questions worth asking

  • Which of the trials of Tenecteplase studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Tenecteplase are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

Where else this substance is registered

FDA substance identifier (UNII)
WGD229O42W
CAS registry number
191588-94-0
ChEMBL
CHEMBL2108791
WHO international nonproprietary name list entry
7769
RxNorm concept
259280
EMA substance identifier
100000085233
DrugBank
DB00031

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Written into the record, not signed off.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Not passed

    Safety mode resolved

    No register row and no identity class settled the question.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 1 approved application covers products containing this substance. The earliest was BLA103909, approved 20000602 to GENENTECH.

    Drugs@FDA application register · BLA103909 · read 2026-08-29

  • Marketing status on the register: prescription.

    Drugs@FDA application register · BLA103909 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 20000602.

    FDA National Drug Code directory · 12714-234 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (10)

On the Tenecteplase label: indicated for what?


"TNKase ® is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). TNKase is a tissue plasminogen activator, indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).": indications and usage on Tenecteplase's label. DailyMed label · 739a3c53-caf6-40d6-a6af-84ce733a948b · 2025-12-15

90 registered trials of Tenecteplase — at which phases?


Registered studies posting no result
75 of 90

90 registered studies of Tenecteplase: 57 phase3, 23 phase2, 8 na or unstated, 6 phase4, 2 phase1, 1 na. CLINICALTRIALS_SNAPSHOT · 2026-09-01

193 with a PubMed record

Show the evidence
  • phase3
    57
  • phase2
    23
  • na or unstated
    8
  • phase4
    6
  • phase1
    2
  • na
    1
6 more recorded rows
  • completed
    42
  • recruiting
    20
  • not yet recruiting
    9
  • terminated
    9
  • unknown
    7
  • withdrawn
    3

recorded 2026-09-01 · last checked 2026-09-04

9 of Tenecteplase's trials stopped: safety, futility/efficacy, accrual/recruitment, other?


safety (1), futility/efficacy (3), accrual/recruitment (2) and other (3): Tenecteplase's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"competitor study about to start"; 9 of 90 registered studies

Show the evidence

Trial

  • NCT00222651
    terminated; "competitor study about to start"
  • NCT00252239
    terminated; "Slow enrollment"
  • NCT00431379
    withdrawn; "drug has expired, no enrollments in study. Company pulled funding"
  • NCT02338466
    withdrawn; "Departure of the principal investigator and lack of succession"
  • NCT03854500
    terminated; "Per protocol safety analysis 200 patients showed a significant difference in bleeding rates between the two drug groups."
  • NCT04454788
    terminated; "Loss of equipoise in the 0-4.5h population which comprised the majority of ETERNAL-LVO trial recruitment due to publication of other trials demonstrating efficacy of tenecteplase vs alteplase in the 0-4.5h time window."
3 further recorded trials
  • NCT04558125
    terminated; "Identification of eligible patients was slower than anticipated."
  • NCT04965038
    terminated; "Stopped after prespecified interim analysis due to futility"
  • NCT05657457
    terminated; "The interim analysis showed the potential harm of intra-arterial TNK."

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Tenecteplase used Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg) — over how long?


Human studies of Tenecteplase used "Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)". ClinicalTrials.gov · 2026-09-01

6 recorded entries; human; also "tenecteplase (0.25 mg/kg, Max 25 mg)", "Tenecteplase (0.25mg/kg)", "Tenecteplase (0.0938mg/kg)"

Show the evidence

human

  • NCT02101606
    Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
  • NCT05141305
    tenecteplase (0.25 mg/kg, Max 25 mg)
  • NCT05635786
    Tenecteplase (0.25mg/kg)
  • NCT07471282
    Tenecteplase (0.0938mg/kg)
  • NCT07606807
    Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)
  • NCT07748039
    rhTNK-tPA (0.25mg/kg)

recorded 2026-09-01 · last checked 2026-09-04

Tenecteplase's half-life is 90 to 130 minutes — which schedules were studied?


90 to 130 minutes, the half-life Tenecteplase's label states: "Elimination After IV bolus administration, the terminal phase half-life of tenecteplase was 90 to 130 minutes." DailyMed label · 739a3c53-caf6-40d6-a6af-84ce733a948b · 2025-12-15

Show the evidence
  • half life pharmacokinetics
    90 to 130 minutes; Elimination After IV bolus administration, the terminal phase half-life of tenecteplase was 90 to 130 minutes.
  • metabolism pharmacokinetics
    Metabolism Liver metabolism is the major clearance mechanism for tenecteplase.

recorded 2025-12-15 · last checked 2026-09-04

Which running trial of Tenecteplase could settle lifespan?


NCT03998319 measures To compare the number of participants who experience cardiovascular mortality and rehospitalisation for heart failure at 24 months in those given tenecteplase with those given placebo (Cardiac MRI cohort only), reading out 2026-12-31.

1 open trial; n 445; "A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients."

Show the evidence
  • Trial NCT03998319
    "A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients."; n 445; "To compare the number of participants who experience cardiovascular mortality and rehospitalisation for heart failure at 24 months in those given tenecteplase with those given placebo (Cardiac MRI cohort only)"; 2026-12-31

Which 16 trials of Tenecteplase posted no result?


Posted no result
16 of 16 completed trials
Registrations
NCT00148460, NCT01472926, NCT00639743, NCT01949948, NCT02101606 and NCT02388061, and 10 more
Completion dates
oldest 2006-02; newest 2024-02-09
Show the evidence

Trial

  • NCT00148460
    2006-02
  • NCT01472926
    2013-12-10
  • NCT00639743
    2014-11
  • NCT01949948
    2016-12-31
  • NCT02101606
    2017-11
  • NCT02388061
    2018-02
10 further recorded trials
  • NCT03677466
    2019-03-20
  • NCT03340493
    2020-02-01
  • NCT04676659
    2020-07-10
  • NCT04071613
    2021-11-16
  • NCT04752631
    2022-07-24
  • NCT03889249
    2023-04-30
  • NCT04516993
    2023-09-30
  • NCT05684172
    2023-11-24
  • NCT02814409
    2024-01-10
  • NCT05141305
    2024-02-09

At the median, Tenecteplase's trials enrolled 330 people — anything larger?


Median enrolment
330
Largest enrolment
10000
Registered trials counted
90

What do 253 spontaneous reports say about Tenecteplase — and not say?


These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Tenecteplase appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 253 reaction mentions were counted: cerebral haemorrhage 56; haemorrhage intracranial 28; electrocardiogram st segment elevation 26; ischaemic stroke 22. FAERS via Open Targets · CHEMBL2108791 · 2026-06-24

Show the evidence
  • cerebral haemorrhage
    56
  • haemorrhage intracranial
    28
  • electrocardiogram st segment elevation
    26
  • ischaemic stroke
    22
  • angioedema
    21
  • hypotension
    21
4 more recorded rows
  • cerebrovascular accident
    20
  • chest pain
    20
  • wrong drug administered
    20
  • haemorrhage
    19

recorded 2026-06-24 · last checked 2026-09-04

Which 10 reactions does Tenecteplase's label not list?


angioedema, cerebral haemorrhage and cerebrovascular accident and 7 more reported for Tenecteplase, absent from its label. FAERS via Open Targets · CHEMBL2108791 · 2026-06-24

2 label terms; 10 reported and unlisted; 739a3c53-caf6-40d6-a6af-84ce733a948b

Show the evidence
  • angioedema
    count not stated
  • cerebral haemorrhage
    count not stated
  • cerebrovascular accident
    count not stated
  • chest pain
    count not stated
  • electrocardiogram st segment elevation
    count not stated
  • haemorrhage
    count not stated
4 more recorded rows
  • haemorrhage intracranial
    count not stated
  • hypotension
    count not stated
  • ischaemic stroke
    count not stated
  • wrong drug administered
    count not stated

recorded 2026-06-24 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL2108791
CAS number
191588-94-0
RxCUI
259280
Trade name
Metalyse, Tenecteplase boehringer ingelheim pharma gmbh co. kg
Also called
Rhtnk-tpa, Tenecteplasa, ia tenecteplase, ia tnk, mingfule, recombinant human tenecteplase tissue-type plasminogen activator, recombinant human tnk tissue-type plasminogen activator, tnk, tnk-tissue plasminogen activator, tnkase, 103-L-ASPARAGINE-117-L-GLUTAMINE-296-L-ALANINE-297-L-ALANINE-298-L-ALANINE-299-L-ALANINEPLASMINOGEN ACTIVATOR (HUMAN TISSUE TYPE), Recombinant tissue plasminogen activator variant (T103N,N117Q, KHRR(296-299)AAAA)
Development code
TNK-TPA
Sources (6)

Sources

ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 6 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.